IP Library Patent Application 14860042
Patent Application
App. No. 14/860,042

RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHODS OF PREPARING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/860,042
Abstract

Methods of isolating highly sialylated recombinant vitamin K dependent proteins, particularly Factor IX, by chromatographic methods are described. The highly sialylated recombinant proteins are characterized. The improved Factor IX has at least 62% N-glycosylation with 3 or 4 sialic acid residues and improved bioavailability and pharmokinetic properties.

Claims (15)

1 . A method of isolating recombinant Factor IX for treatment of hemophilia comprising:

providing a preparation of recombinant Factor IX; and

separating forms of recombinant Factor IX with 3 or more sialic acid residues per N-glycan;

collecting fractions enriched in recombinant Factor IX with 3 or more sialic acid residues per N-glycan; and

pooling the fractions having recombinant Factor IX, wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 50%.

2 . The method of claim 1 , wherein the separation is carried out by chromatography.

3 . The method of claim 2 , wherein the chromatography is carried out in the presence of calcium.

4 . The method of claim 1 , wherein the Factor IX is fully gamma-carboxylated.

5 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 62%.

6 .- 19 . (canceled)

20 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 65%.

21 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 75%.

22 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 85%.

23 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is at least 95%.

24 . The method of claim 1 , wherein the percentage of N-linked glycans with 3 or more sialic acid residues is 100%.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →
SECURITY INTEREST Recorded Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
MERGER Recorded Dec 14, 2016
From: CNJ HOLDINGS INC.
To: CANGENE CORPORATION
Reel/Frame 040735/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: CANGENE CORPORATION
To: 407850 MANITOBA PARTNERSHIP
Reel/Frame 040735/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: CANGENE CORPORATION; 407850 MANITOBA PARTNERSHIP; EMERGENT PROTECTIVE PRODUCTS CANADA ULC
To: APTEVO BIOTHERAPEUTICS LLC
Reel/Frame 040735/0833 →